Item Type | Name |
Concept
|
Molecular Biology
|
Concept
|
Receptors, Cell Surface
|
Concept
|
Receptors, Antigen, B-Cell
|
Concept
|
Receptors, Immunologic
|
Concept
|
Receptors, Opioid, mu
|
Concept
|
Receptors, Eph Family
|
Concept
|
Receptors, Fibroblast Growth Factor
|
Concept
|
Receptors, Growth Factor
|
Concept
|
Toll-Like Receptor 3
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
Concept
|
Receptors, CXCR4
|
Concept
|
Lipopolysaccharide Receptors
|
Concept
|
Receptor, ErbB-3
|
Concept
|
Vascular Endothelial Growth Factor Receptor-2
|
Concept
|
Systems Biology
|
Concept
|
Receptors, Thrombopoietin
|
Concept
|
Receptors, Interleukin-8A
|
Concept
|
Receptors, Interleukin-8B
|
Concept
|
Receptors, Notch
|
Concept
|
Interleukin Receptor Common gamma Subunit
|
Concept
|
Receptor, EphB4
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
Concept
|
Receptors, Cytokine
|
Concept
|
Receptors, Interleukin
|
Concept
|
Receptor, ErbB-2
|
Concept
|
Protein Tyrosine Phosphatase, Non-Receptor Type 6
|
Concept
|
Receptors, Chemokine
|
Concept
|
Receptors, Calcitriol
|
Concept
|
Receptor, EphA2
|
Concept
|
Receptors, Lysophosphatidic Acid
|
Concept
|
Programmed Cell Death 1 Receptor
|
Concept
|
Hyaluronan Receptors
|
Concept
|
Computational Biology
|
Concept
|
Vascular Endothelial Growth Factor Receptor-1
|
Concept
|
Receptors, Lysosphingolipid
|
Concept
|
Protein Tyrosine Phosphatase, Non-Receptor Type 11
|
Concept
|
Protein Tyrosine Phosphatase, Non-Receptor Type 12
|
Academic Article
|
The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors.
|
Academic Article
|
Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells.
|
Academic Article
|
Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells.
|
Academic Article
|
Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells.
|
Academic Article
|
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
|
Academic Article
|
The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo.
|
Academic Article
|
A cdc15-like adaptor protein (CD2BP1) interacts with the CD2 cytoplasmic domain and regulates CD2-triggered adhesion.
|
Academic Article
|
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
|
Academic Article
|
Role of the cytoskeletal protein paxillin in oncogenesis.
|
Academic Article
|
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
|
Academic Article
|
Role of receptor tyrosine kinases in lung cancer.
|
Academic Article
|
Molecular alterations in lung cancer. Impact on prognosis.
|
Academic Article
|
Small cell lung cancer: from molecular biology to novel therapeutics.
|
Academic Article
|
Therapeutic targeting of the receptor tyrosine kinase Met.
|
Academic Article
|
Novel therapies in lung cancer.
|
Academic Article
|
Molecular biology of malignant mesothelioma: a review.
|
Academic Article
|
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
|
Academic Article
|
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.
|
Academic Article
|
Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors.
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
Academic Article
|
Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue.
|
Academic Article
|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
|
Academic Article
|
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
|
Academic Article
|
Biology and novel therapeutics for neuroendocrine tumors of the lung.
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
Academic Article
|
Receptor tyrosine kinases and inhibitors in lung cancer.
|
Academic Article
|
The role of ephrins and Eph receptors in cancer.
|
Academic Article
|
Expression and mutational analysis of MET in human solid cancers.
|
Academic Article
|
MET pathway as a therapeutic target.
|
Academic Article
|
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.
|
Academic Article
|
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
|
Academic Article
|
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
|
Academic Article
|
PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.
|
Academic Article
|
MET receptor tyrosine kinase.
|
Academic Article
|
Ethnic differences and functional analysis of MET mutations in lung cancer.
|
Academic Article
|
The role of chemokine receptor CXCR4 in lung cancer.
|
Academic Article
|
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
|
Academic Article
|
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
|
Academic Article
|
The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation.
|
Academic Article
|
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.
|
Academic Article
|
Non-receptor tyrosine kinase inhibitors in lung cancer.
|
Academic Article
|
Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways.
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
Academic Article
|
A novel classification of lung cancer into molecular subtypes.
|
Academic Article
|
Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.
|
Academic Article
|
Differential expression of RON in small and non-small cell lung cancers.
|
Academic Article
|
PAX3 and SOX10 activate MET receptor expression in melanoma.
|
Academic Article
|
Therapeutic targeting of receptor tyrosine kinases in lung cancer.
|
Academic Article
|
MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.
|
Academic Article
|
The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization.
|
Academic Article
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
Academic Article
|
CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancer.
|
Academic Article
|
Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions.
|
Academic Article
|
Role of protein kinase C ß and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
|
Academic Article
|
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
Academic Article
|
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
|
Academic Article
|
Tyrosine kinase mutations in human cancer.
|
Academic Article
|
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases.
|
Academic Article
|
Personalized treatment of lung cancer.
|
Academic Article
|
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.
|
Academic Article
|
Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer.
|
Academic Article
|
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
|
Academic Article
|
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
|
Academic Article
|
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
|
Academic Article
|
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
|
Academic Article
|
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
|
Academic Article
|
Molecular and cellular biology of small cell lung cancer.
|
Academic Article
|
Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer.
|
Academic Article
|
Key signaling pathways and targets in lung cancer therapy.
|
Academic Article
|
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.
|
Academic Article
|
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
|
Academic Article
|
Novel targets for therapeutic agents in small cell lung cancer.
|
Academic Article
|
The role of EGFR inhibition in the treatment of non-small cell lung cancer.
|
Academic Article
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
Academic Article
|
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
Academic Article
|
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.
|
Academic Article
|
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
|
Academic Article
|
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
|
Academic Article
|
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.
|
Academic Article
|
Critical role of S1PR1 and integrin ß4 in HGF/c-Met-mediated increases in vascular integrity.
|
Academic Article
|
EphB4 as a therapeutic target in mesothelioma.
|
Academic Article
|
TLR3 agonists and proinflammatory antitumor activities.
|
Academic Article
|
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
|
Academic Article
|
Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression.
|
Academic Article
|
Increased µ-opioid receptor expression in metastatic lung cancer.
|
Academic Article
|
The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.
|
Academic Article
|
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
|
Academic Article
|
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
|
Academic Article
|
Mitochondrial dynamics: biology and therapy in lung cancer.
|
Academic Article
|
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer.
|
Academic Article
|
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
|
Academic Article
|
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.
|
Academic Article
|
Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.
|
Academic Article
|
AXL mediates resistance to cetuximab therapy.
|
Academic Article
|
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
|
Academic Article
|
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
|
Academic Article
|
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
|
Academic Article
|
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
|
Academic Article
|
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
|
Academic Article
|
PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma.
|
Academic Article
|
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
|
Academic Article
|
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.
|
Academic Article
|
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
|
Academic Article
|
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
|
Academic Article
|
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
|
Academic Article
|
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
|
Academic Article
|
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
|
Academic Article
|
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
|
Academic Article
|
RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
|
Academic Article
|
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
|
Academic Article
|
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
|
Academic Article
|
Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC).
|
Academic Article
|
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
|
Academic Article
|
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
|
Academic Article
|
Value-Based Medicine and Integration of Tumor Biology.
|
Academic Article
|
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
|
Academic Article
|
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
|
Academic Article
|
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
|
Academic Article
|
EphB4: A promising target for upper aerodigestive malignancies.
|
Academic Article
|
Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models.
|
Academic Article
|
Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone.
|
Academic Article
|
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
|
Academic Article
|
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
|
Academic Article
|
Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer.
|
Academic Article
|
Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology.
|
Academic Article
|
Notch signaling in breast cancer: From pathway analysis to therapy.
|
Academic Article
|
Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer.
|
Academic Article
|
RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis.
|
Academic Article
|
Precision medicine and actionable alterations in lung cancer: A single institution experience.
|
Academic Article
|
Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases.
|
Academic Article
|
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
|
Academic Article
|
Opportunities for improving cancer treatment using systems biology.
|
Academic Article
|
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion.
|
Academic Article
|
MET receptor in oncology: From biomarker to therapeutic target.
|
Academic Article
|
Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP.
|
Academic Article
|
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
|
Academic Article
|
Quantifying Cancer: More Than Just a Numbers Game.
|
Academic Article
|
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
|
Academic Article
|
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
|
Academic Article
|
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.
|
Academic Article
|
Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer.
|
Academic Article
|
Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor.
|
Academic Article
|
MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis.
|
Academic Article
|
Addressing the genetic/nongenetic duality in cancer with systems biology.
|
Academic Article
|
A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer.
|
Academic Article
|
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
|
Concept
|
Endothelin Receptor Antagonists
|
Concept
|
ErbB Receptors
|
Grant
|
Role of Paxillin in Lung Cancer
|
Grant
|
Role of c-Met in SCLC and Potential for Novel Therapy
|
Grant
|
Novel Targeted Therapy in Pancreatic Cancer
|
Grant
|
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
|
Grant
|
PAXILLIN--AN ONCOGENE ACTIVATED PROTEIN
|
Academic Article
|
Clinical Network Systems Biology: Traversing the Cancer Multiverse.
|